Expert Answers to Questions on PARP Inhibition for Prostate Cancer

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:Germline and somatic mutation testingManaging adverse events with PARP inhibitorsResistance to PARP inhibitorsImplications of monoallelic vs biallelic BRCA mutationsATM mutations and PARP inhibitor sensitivityPresenters:Charles J. Ryan, MDProfessor of MedicineB.J. Kennedy Chair in Clinical Medical OncologyDirector, Division of Hematology, Oncology and TransplantationDepartment of MedicineUniversity of MinnesotaOncologistDivision of Hematology, Oncology and TransplantationUniversity of Minnesota Health Clinics and Surgery CenterMinneapolis, MinnesotaNeal D. Shore, MD, FACSDirectorCarolina Urologic Research CenterAtlantic Urology ClinicsMyrtle Beach, South CarolinaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/2P31ZqF

There are no comments yet.

Please log in to write the first comment.